CD36 as a marker of acute myeloid leukemia prognosis: A systematic review

CD36 is a glycoprotein associated with resistance to chemotherapy and the recurrence of acute myeloid leukemia. This systematic review aims to evaluate the impact of CD36 on the prognosis of acute myeloid leukemia, a complex heterogeneous malignant hematopoietic disease. The Embase, Scopus, Web of S...

Full description

Saved in:
Bibliographic Details
Main Authors: Marina Chaves Amantéa, Rafaela Pires da Silva, Larissa Ranini Soares, João Lorenzo de Medeiros Pereira, Ana Paula Duarte de Souza
Format: Article
Language:English
Published: Elsevier 2025-07-01
Series:Hematology, Transfusion and Cell Therapy
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2531137925001294
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849390645590884352
author Marina Chaves Amantéa
Rafaela Pires da Silva
Larissa Ranini Soares
João Lorenzo de Medeiros Pereira
Ana Paula Duarte de Souza
author_facet Marina Chaves Amantéa
Rafaela Pires da Silva
Larissa Ranini Soares
João Lorenzo de Medeiros Pereira
Ana Paula Duarte de Souza
author_sort Marina Chaves Amantéa
collection DOAJ
description CD36 is a glycoprotein associated with resistance to chemotherapy and the recurrence of acute myeloid leukemia. This systematic review aims to evaluate the impact of CD36 on the prognosis of acute myeloid leukemia, a complex heterogeneous malignant hematopoietic disease. The Embase, Scopus, Web of Science, Cochrane Library and SciELO databases were searched until September 2023. Only studies that analyzed CD36 expression in humans were included. Of 905 articles identified from the databases, 600 were screened and nine were included. The Newcastle-Ottawa Scale was used to evaluate the methodological quality of the studies. According to this systematic review, CD36 is associated with different prognostic factors in acute myeloid leukemia, including remission and relapse of the disease, overall survival, and chemoresistance.
format Article
id doaj-art-e30f11ddb7304a7dbcd829ef88ad4b92
institution Kabale University
issn 2531-1379
language English
publishDate 2025-07-01
publisher Elsevier
record_format Article
series Hematology, Transfusion and Cell Therapy
spelling doaj-art-e30f11ddb7304a7dbcd829ef88ad4b922025-08-20T03:41:26ZengElsevierHematology, Transfusion and Cell Therapy2531-13792025-07-0147310386110.1016/j.htct.2025.103861CD36 as a marker of acute myeloid leukemia prognosis: A systematic reviewMarina Chaves Amantéa0Rafaela Pires da Silva1Larissa Ranini Soares2João Lorenzo de Medeiros Pereira3Ana Paula Duarte de Souza4Escola de Ciências da Saúde e da Vida, Pontifícia Universidade Católica do Rio Grande do Sul (PUCRS), Porto Alegre, RS, BrazilEscola de Ciências da Saúde e da Vida, Pontifícia Universidade Católica do Rio Grande do Sul (PUCRS), Porto Alegre, RS, BrazilEscola de Ciências da Saúde e da Vida, Pontifícia Universidade Católica do Rio Grande do Sul (PUCRS), Porto Alegre, RS, BrazilEscola de Ciências da Saúde e da Vida, Pontifícia Universidade Católica do Rio Grande do Sul (PUCRS), Porto Alegre, RS, BrazilCorresponding author. Laboratory of Clinical and Experimental Immunology, Health and Life Science School, Pontifical Catholic University of Rio Grande do Sul – Av. Ipiranga, 6681, CEP 90619-900, Porto Alegre, RS, Brazil.; Escola de Ciências da Saúde e da Vida, Pontifícia Universidade Católica do Rio Grande do Sul (PUCRS), Porto Alegre, RS, BrazilCD36 is a glycoprotein associated with resistance to chemotherapy and the recurrence of acute myeloid leukemia. This systematic review aims to evaluate the impact of CD36 on the prognosis of acute myeloid leukemia, a complex heterogeneous malignant hematopoietic disease. The Embase, Scopus, Web of Science, Cochrane Library and SciELO databases were searched until September 2023. Only studies that analyzed CD36 expression in humans were included. Of 905 articles identified from the databases, 600 were screened and nine were included. The Newcastle-Ottawa Scale was used to evaluate the methodological quality of the studies. According to this systematic review, CD36 is associated with different prognostic factors in acute myeloid leukemia, including remission and relapse of the disease, overall survival, and chemoresistance.http://www.sciencedirect.com/science/article/pii/S2531137925001294Acute myeloid leukemiaAntigenCd36PrognosisPrognostic factors
spellingShingle Marina Chaves Amantéa
Rafaela Pires da Silva
Larissa Ranini Soares
João Lorenzo de Medeiros Pereira
Ana Paula Duarte de Souza
CD36 as a marker of acute myeloid leukemia prognosis: A systematic review
Hematology, Transfusion and Cell Therapy
Acute myeloid leukemia
Antigen
Cd36
Prognosis
Prognostic factors
title CD36 as a marker of acute myeloid leukemia prognosis: A systematic review
title_full CD36 as a marker of acute myeloid leukemia prognosis: A systematic review
title_fullStr CD36 as a marker of acute myeloid leukemia prognosis: A systematic review
title_full_unstemmed CD36 as a marker of acute myeloid leukemia prognosis: A systematic review
title_short CD36 as a marker of acute myeloid leukemia prognosis: A systematic review
title_sort cd36 as a marker of acute myeloid leukemia prognosis a systematic review
topic Acute myeloid leukemia
Antigen
Cd36
Prognosis
Prognostic factors
url http://www.sciencedirect.com/science/article/pii/S2531137925001294
work_keys_str_mv AT marinachavesamantea cd36asamarkerofacutemyeloidleukemiaprognosisasystematicreview
AT rafaelapiresdasilva cd36asamarkerofacutemyeloidleukemiaprognosisasystematicreview
AT larissaraninisoares cd36asamarkerofacutemyeloidleukemiaprognosisasystematicreview
AT joaolorenzodemedeirospereira cd36asamarkerofacutemyeloidleukemiaprognosisasystematicreview
AT anapauladuartedesouza cd36asamarkerofacutemyeloidleukemiaprognosisasystematicreview